| Umsatz in Mio. | 837,60 $ |
| Operatives Ergebnis (EBIT) in Mio. | -122,40 $ |
| Jahresüberschuss in Mio. | -127,30 $ |
| Umsatz je Aktie | 9,19 $ |
| Gewinn je Aktie | -1,40 $ |
| Gewinnrendite | -18,16% |
| Umsatzrendite | - |
| Return on Investment | -12,39% |
| Marktkapitalisierung in Mio. | 1.249 $ |
| KGV (Kurs/Gewinn) | -9,79 |
| KBV (Kurs/Buchwert) | 1,78 |
| KUV (Kurs/Umsatz) | 1,49 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +68,23% |
| Geld/Brief | 5,65 € / 5,80 € |
| Spread | +2,65% |
| Schluss Vortag | 5,75 € |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief 5,55 € Tageshoch 5,775 € | |
| 52W-Tief 3,26 € 52W-Hoch 14,80 € | |
| Jahrestief 3,26 € Jahreshoch 14,80 € | |
| 31.12.2025 | Quartalsmitteilung |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 5,50 € | -3,51% | 5,70 € | 23.12.25 | |
| Frankfurt | 5,70 € | -1,72% | 5,80 € | 23.12.25 | |
| Hamburg | 5,55 € | -3,48% | 5,75 € | 23.12.25 | |
| Hannover | 5,55 € | -3,48% | 5,75 € | 23.12.25 | |
| München | 5,70 € | +0,88% | 5,65 € | 23.12.25 | |
| Stuttgart | 5,65 € | -2,59% | 5,80 € | 23.12.25 | |
| L&S RT | 5,725 € | -0,43% | 5,75 € | 23.12.25 | |
| Berlin | 5,65 € | +2,73% | 5,50 € | 23.12.25 | |
| NYSE | 6,56 $ | -3,17% | 6,775 $ | 23.12.25 | |
| Nasdaq | 6,56 $ | -2,96% | 6,76 $ | 23.12.25 | |
| AMEX | 6,565 $ | -3,17% | 6,78 $ | 23.12.25 | |
| Tradegate | 5,50 € | -1,79% | 5,60 € | 22.12.25 | |
| Quotrix | 5,75 € | +2,68% | 5,60 € | 23.12.25 | |
| Gettex | 5,60 € | -2,61% | 5,75 € | 23.12.25 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 23.12.25 | 5,725 | - |
| 22.12.25 | 5,75 | - |
| 21.12.25 | 5,60 | - |
| 20.12.25 | 5,60 | - |
| 19.12.25 | 5,625 | - |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 5,925 € | -3,38% |
| 1 Monat | 6,70 € | -14,55% |
| 6 Monate | 4,39 € | +30,41% |
| 1 Jahr | 13,15 € | -56,46% |
| 5 Jahre | 15,2125 € | -62,37% |
| Marktkapitalisierung | 523,33 Mio. € |
| Aktienanzahl | 91,04 Mio. |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Aktientyp | Stammaktie |
| +16,20% | BlackRock Inc |
| +9,95% | Vanguard Group Inc |
| +5,29% | Millennium Management LLC |
| +5,17% | State Street Corp |
| +4,93% | Glenview Capital Management LLC |
| +4,89% | Morgan Stanley - Brokerage Accounts |
| +4,85% | D. E. Shaw & Co LP |
| +2,39% | Geode Capital Management, LLC |
| +2,23% | Dimensional Fund Advisors, Inc. |
| +2,21% | Qube Research & Technologies |
| +2,15% | Camber Capital Management LLC |
| +1,84% | Citadel Advisors Llc |
| +1,49% | Connor Clark & Lunn Inv Mgmt Ltd |
| +1,45% | Anson Funds Management LP |
| +1,44% | Charles Schwab Investment Management Inc |
| +1,39% | Fisher Asset Management, LLC |
| +1,38% | Goldman Sachs Group Inc |
| +1,34% | Kent Lake PR LLC |
| +1,25% | Portolan Capital Management, LLC |
| +1,21% | Federated Hermes Inc |
| +26,96% | Weitere |
| 0,00% | Streubesitz |
prüft strategische Alternativen für sein Autoimmun-Geschäft
https://www.thestreet.com/investing/myriad-genetics-rises-on-strategic-options-effort-for-autoimmune-unit
Zahlen für "Q4"/20
"As a result, the company has decided to not provide fiscal year 2021 financial guidance."
https://myriad.com/investors/news-release/news-release-detail/?newsItemId=21356
FDA Zulassung für BRACAnalysis CDx®
https://myriad.com/investors/news-release/news-release-detail/?newsItemId=21181